Naltrexone Is Superior to Placebo for Abstinence and Craving Reduction in Alcohol‐Associated Cirrhosis: NAL ‐ CI Trial
Liver International · 2026
DOI: 10.1111/liv.70845 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Liver International, 2026. Verfasst von Manasa Alla und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatology, Institute of Liver and Biliary Sciences, New Delhi, India. Hauptthemen laut MEDLINE: Naltrexone, Craving, Narcotic Antagonists, Liver Cirrhosis, Alcoholic. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background and Aims Alcohol use disorder (AUD) coexisting with cirrhosis carries high morbidity and mortality, with no approved pharmacotherapy for AUD. We evaluated the safety and efficacy of naltrexone, an opioid receptor antagonist, in patients with compensated alcohol‐associated cirrhosis (AaC) and AUD.
Methods
One hundred patients with compensated AaC and DSM‐5 AUD were randomised 1:1 to naltrexone (50 mg/day) or placebo for 12 weeks. The primary endpoint was point‐prevalence abstinence at 12 weeks, defined as no alcohol use in the four preceding weeks. Secondary endpoints included craving (Obsessive Compulsive Drinking Scale [OCDS]—Obsessive and Compulsive subscales), lapses, relapses, and hepatic safety. Standardised psychosocial support was provided to both arms.
Results
Baseline characteristics were well matched between groups (mean MELD 12.6 vs. 12.7; CTP score 5.9 vs. 6.2; age 42.9 vs. 44.3 years). AUDIT and OCDS scores were comparable between groups. Abstinence at 12 weeks was significantly higher with naltrexone: 64% (32/50) versus 22% (11/50), p < 0.001; OR 10.86 (95% CI: 1.89–62.2). Naltrexone significantly reduced lapses at 3 months (28% vs. 54%, p = 0.008) and showed a trend toward fewer heavy‐drinking relapses (12% vs. 28%, p = 0.07). Maintenance of abstinence at 6 months favoured naltrexone (22% vs. 8%, p = 0.09). No patient developed hepatic decompensation attributable to study medication, and no AST/ALT elevation exceeding 5× ULN was observed in either group. Mean craving scores were lower with naltrexone by week 12 than with placebo: OCDS‐O score (6.63 ± 1.16 vs. 9.29 ± 1.78, p < 0.01) and OCDS‐C score (6.35 ± 1.23 vs. 9.02 ± 1.86, p < 0.01). Adverse events were comparable between the groups.
Conclusion
Naltrexone is safe and effective in patients with compensated alcohol‐associated cirrhosis, achieving a threefold higher abstinence rate and significantly reducing craving compared with placebo. These findings support the use of naltrexone as a pharmacological option in patients with compensated AaC and AUD. Trial Registration NCT04391764
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hepatology, Institute of Liver and Biliary Sciences, New Delhi, India.
- Department of Psychiatry, Institute of Liver and Biliary Sciences, New Delhi, India.
- Department of Clinical Research and Biostatistics, Institute of Liver and Biliary Sciences, New Delhi, India.
ORCID-Profile: Manasa Alla, Mohit Varshney, Ankit Bhardwaj, S M Shasthry, Shiv Kumar Sarin
Zitieren
APA
Alla, M., Varshney, M., Bhardwaj, A., Kumar, G., Shasthry, S. M., & Sarin, S. K. (2026). Naltrexone Is Superior to Placebo for Abstinence and Craving Reduction in Alcohol‐Associated Cirrhosis: NAL ‐ CI Trial. Liver International. https://doi.org/10.1111/liv.70845
Vancouver
Alla M, Varshney M, Bhardwaj A, Kumar G, Shasthry SM, Sarin SK. Naltrexone Is Superior to Placebo for Abstinence and Craving Reduction in Alcohol‐Associated Cirrhosis: NAL ‐ CI Trial. Liver International. 2026. doi:10.1111/liv.70845
BibTeX
@article{Alla2026,
author = {Alla, Manasa and Varshney, Mohit and Bhardwaj, Ankit and Kumar, Guresh and Shasthry, S M and Sarin, Shiv Kumar},
title = {Naltrexone Is Superior to Placebo for Abstinence and Craving Reduction in Alcohol‐Associated Cirrhosis: NAL ‐ CI Trial},
journal = {Liver International},
year = {2026},
doi = {10.1111/liv.70845}
}
EUVIMED